Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas

Chun I. Sze, Wan Pei Su, Ming Fu Chiang, Chen Yu Lu, Yu An Chen, Nan Shan Chang

Research output: Contribution to journalShort surveypeer-review

14 Citations (Scopus)


Unique astrocytic cell infiltrating growth and glial tumor growth in the confined skull make human glioblastoma (GBM) one of the most difficult cancers to treat in modern medicine. Prognosis for patients is very poor, as they die more or less within 12 months. Patients either die of the cancer itself, or secondary complications such as cerebral edema, herniations, or hemorrhages. GBMs rarely metastasize to other organs. However, GBM recurrence associated with resistance to therapeutic drugs is common. Patients die shortly after relapse. GBM is indeed an outstanding cancer model to search for potential mechanisms for drug resistance. Here, we reviewed the current cancer biology of gliomas and their pathophysiological events that contribute to the development of therapeutic resistance. We have addressed the potential roles of cancer stem cells, epigenetic modifications, and epithelial mesenchymal transition (EMT) in the development of resistance to inhibitor drugs in GBMs. The potential role of TIAF1 (TGF-β-induced antiapoptotic factor) overexpression and generation of intratumor amyloid fibrils for conferring drug resistance in GBMs is discussed.

Original languageEnglish
Article numberArticle 00059
JournalFrontiers in Oncology
Volume3 MAR
Publication statusPublished - 2013

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas'. Together they form a unique fingerprint.

Cite this